Milestone an important step in launching Trinovium within the global AI data center ecosystem-Data center liquid cooling market projected to ...

Trinity Biotech plc (Nasdaq: TRIB), a commercial stage biotechnology company focused on human diagnostics and the development of innovative solutions addressing unmet clinical and industrial needs, ...

Trinity Biotech, a Nasdaq-listed biotechnology company focused on human diagnostics and diabetes management solutions, this ...

New subsidiary will leverage existing US and EU manufacturing capacity, high-purity fluid expertise, and analytical technologies to target liquid cooling performance and reliability in AI and ...

Trinity Biotech plc, a biotechnology company specializing in human diagnostics and diabetes management, announced it has secured an additional $4 million in debt financing from Perceptive Advisors.

Trinity Biotech plc announced revised agreements with its primary lender, Perceptive Advisors, to improve its financial position as the company implements its Comprehensive Transformation Plan and ...

DUBLIN, June 16, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including ...

Designed for personal research, portfolio monitoring, and AI-assisted investment workflows. Trinity Biotech ( (TRIB) ) has issued an update.

Tuesday, Trinity Biotech plc (NASDAQ:TRIB) stock is trading higher with a session volume of 14.32 million versus the average volume of 118.9K as per data from Benzinga Pro. The company received ...

Trinity Biotech plc (NASDAQ: TRIB) stock surged Tuesday after the diagnostics company announced a pair of developments that significantly altered its near- and long-term outlook. Investors reacted ...

DUBLIN, Ireland, May 08, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (TRIB) a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable ...

-Trinity Biotech (TRIB) projects it reached Adjusted EBITDA 1-positive operations during Q2 2025 and expects to be Adjusted EBITDA 1 positive going forward, reflecting continued strong execution on ...